Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Clinical Pharmacology in Drug Development
|
August 25, 2021
The Effect of Food on the Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan
Darcy J Mulford, Eckhard Leifke, Mark Hibberd, et al.
Journal of Clinical Pharmacology
|
April 1, 2010
Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects
Brian A Grabowski, Reza Khosravan, Laurent Vernillet, et al.
Clinical Pharmacology and Therapeutics
|
April 24, 2003
Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil
Eric P Brass, Michael D Mayer, Darcy J Mulford, et al.
Journal of Chromatographic Science
|
May 15, 2002
Assay of TNP-470 and its two major metabolites in human plasma by high-performance liquid chromatography-mass spectrometry
Carl T Whalen, Glenn D Hanson, Kathy J Putzer, et al.
The American Journal of Gastroenterology
|
March 16, 2022
Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects
Loren Laine, Prateek Sharma, Darcy J Mulford, et al.
Journal of Clinical Pharmacology
|
December 22, 2021
A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure
Carmelo Scarpignato, Eckhard Leifke, Neila Smith, et al.
The American Journal of Gastroenterology
|
November 3, 2022
Response to Graham
Loren Laine, Prateek Sharma, Darcy J Mulford, et al.
American Journal of Therapeutics
|
January 22, 2005
Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment
Michael D Mayer, Reza Khosravan, Laurent Vernillet, et al.
Alimentary Pharmacology & Therapeutics
|
April 17, 2023
A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection
Carmelo Scarpignato, Colin W Howden, Eckhard Leifke, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
June 30, 2026
Development and Use of a Population Pharmacokinetic Model for Characterizing the Pharmacokinetics of Vonoprazan in Pediatric Patients
Darcy J Mulford, Axel Facius, Galen Witt, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Clinical Pharmacology in Drug Development
|
August 25, 2021
The Effect of Food on the Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan
Darcy J Mulford, Eckhard Leifke, Mark Hibberd, et al.
Journal of Clinical Pharmacology
|
April 1, 2010
Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects
Brian A Grabowski, Reza Khosravan, Laurent Vernillet, et al.
Clinical Pharmacology and Therapeutics
|
April 24, 2003
Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil
Eric P Brass, Michael D Mayer, Darcy J Mulford, et al.
Journal of Chromatographic Science
|
May 15, 2002
Assay of TNP-470 and its two major metabolites in human plasma by high-performance liquid chromatography-mass spectrometry
Carl T Whalen, Glenn D Hanson, Kathy J Putzer, et al.
The American Journal of Gastroenterology
|
March 16, 2022
Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects
Loren Laine, Prateek Sharma, Darcy J Mulford, et al.
Journal of Clinical Pharmacology
|
December 22, 2021
A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure
Carmelo Scarpignato, Eckhard Leifke, Neila Smith, et al.
The American Journal of Gastroenterology
|
November 3, 2022
Response to Graham
Loren Laine, Prateek Sharma, Darcy J Mulford, et al.
American Journal of Therapeutics
|
January 22, 2005
Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment
Michael D Mayer, Reza Khosravan, Laurent Vernillet, et al.
Alimentary Pharmacology & Therapeutics
|
April 17, 2023
A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection
Carmelo Scarpignato, Colin W Howden, Eckhard Leifke, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
June 30, 2026
Development and Use of a Population Pharmacokinetic Model for Characterizing the Pharmacokinetics of Vonoprazan in Pediatric Patients
Darcy J Mulford, Axel Facius, Galen Witt, et al.
Page
of 2